Positron Emission Tomography Imaging with $^{18}$F-Labeled $Z_{HER2:2891}$ Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

Sebastian Trousil$^1$, Susan Hoppmann$^2$, Quang-Dé Nguyen$^1$, Maciej Kaliszczak$^1$, Giampaolo Tomasi$^1$, Peter Iveson$^2$, Duncan Hiscock$^2$, Eric O. Aboagye$^1$

$^1$Comprehensive Cancer Imaging Centre at Imperial College, Faculty of Medicine, Imperial College London, United Kingdom

$^2$GE Healthcare, Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, Buckinghamshire, HP7 9LL, U.K.

**Corresponding Author:** Eric O. Aboagye, Comprehensive Cancer Imaging Centre, Faculty of Medicine, Imperial College London, Room GN1, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom. Phone: +44 208 383 3759; Fax: +44 208 383 1783; E-mail: eric.aboagye@imperial.ac.uk

**Running title:** Affibody PET imaging of HER2 and HSP90 inhibition.

**Key words:** HER2, Affibody, $Z_{HER2:2891}$, positron emission tomography, trastuzumab, HSP90, NVP-AUY922.
Financial support: This work was funded by Cancer Research UK - Engineering and Physical Sciences Research Council grant (in association with the Medical Research Council and Department of Health (England)) grant C2536/A10337.

Disclosure of Potential Conflicts of Interest: Susan Hoppmann, Peter Iveson and Duncan Hiscock are employees of GE Healthcare. A patent on this invention has been filed.

Word count (excluding references): 4992.

Total number of figures and tables: 1 Table and 5 Figures.

References: 44.
Translational Relevance

Accurate assessment of a cancer patient’s HER2 status remains a clinical challenge with up to 20% of patients being potentially withdrawn from therapy or exposed to unnecessary toxicity. Non-invasive imaging is widely seen as a viable alternative to current methods, in particular within the setting of locoregional and distant recurrences not amenable to biopsy, but clinical success by positron emission tomography has so far been hampered by prolonged tracer retention in liver and kidneys obstructing detection on proximate metastases. We developed a next-generation Affibody-based radiotracer, \([^{18}F]GE-226\), with improved properties for large-scale and GMP grade synthesis and enhanced pharmacokinetic characteristics. We were able to differentiate HER2 negative from low, medium and high-expressing tumors by imaging and irrespective of trastuzumab pre-treatment. Lineage-independence of these results extends application beyond breast cancer. Due to the specific annotation to HER2 and enhanced pharmacokinetic properties, \([^{18}F]GE-226\) is now transitioning into clinical development.
Abstract

**Purpose:** Expression of HER2 has profound implications on treatment strategies in various types of cancer. We investigated the specificity of radiolabeled HER2-targeting ZHER2:2891 Affibody, [\(^{18}\)F]GE-226, for positron emission tomography (PET) imaging.

**Experimental design:** Intrinsic cellular [\(^{18}\)F]GE-226 uptake and tumor-specific tracer binding were assessed in cells and xenografts with and without drug treatment. Specificity was further determined by comparing tumor localization of a fluorescently labeled analogue with DAKO HercepTest™.

**Results:** [\(^{18}\)F]GE-226 uptake was 11 to 67-fold higher in ten HER2 positive versus negative cell lines in vitro independent of lineage. Uptake in HER2 positive xenografts was rapid with net irreversible binding kinetics making possible the distinction of HER2 negative (MCF7 and MCF7-p95HER2: NUV\(_{60}\) (%ID/mL) 6.1 ± 0.7; \(K_i\) (mL/cm\(^3\)/min) 0.0069 ± 0.0014) from HER2 positive tumors (NUV\(_{60}\) and \(K_i\): MCF7-HER2, 10.9 ± 1.5 and 0.015 ± 0.0035; MDA-MB-361, 18.2 ± 3.4 and 0.025 ± 0.0052; SKOV-3, 18.7 ± 2.4 and 0.036 ± 0.0065) within 1h. Tumor uptake correlated with HER2 expression determined by ELISA (\(r^2 = 0.78\)), and a fluorophore-labled tracer analogue co-localized with HER2 expression. Tracer uptake was not influenced by short-term or continuous treatment with trastuzumab in keeping with differential epitope binding, but reflected HER2 degradation by short-term NVP-AUY922 treatment in SKOV-3 xenografts (NUV\(_{60}\): 13.5 ± 2.1 versus 9.0 ± 0.9 %ID/mL for vehicle or drug, respectively).

**Conclusions:** [\(^{18}\)F]GE-226 binds with high specificity to HER2 independent of cell lineage. The tracer has potential utility for HER2 detection, irrespective of prior trastuzumab treatment, and to discern HSP90 inhibitor-mediated HER2 degradation.
Introduction

Human Epidermal Growth Factor Receptor 2 (HER2, also referred to as HER2/neu or ErbB-2) is a 185 kDa transmembrane receptor belonging to the epidermal growth factor receptor family (1). HER2 gene amplification and protein over-expression play pivotal roles in the pathogenesis and progression of many types of cancer. HER2 is overexpressed in around 20% of breast, 15-35% of gastric and 9-32% of ovarian cancers and is correlated with poor survival (2-4). The protein has consequently emerged in recent years as an important predictive biomarker and target of cancer therapy (5). Homo- or heterodimerization with other members of its family prompts activation of the intracellular tyrosine kinase domain and triggers cell survival and proliferation mediated through MAPK and Akt signaling pathways (6, 7).

Available HER2-targeted therapies in the clinic include antibodies, such as trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta, Genentech), which prevents receptor dimerization, antibody-drug conjugates, such as T-DM1 (Kadcyla, Genentech) or small molecule inhibitors targeting the tyrosine-kinase domain (e.g. lapatinib, Tyverb, GlaxoSmithKline; a dual HER2 and EGFR inhibitor). Proteolytic shedding of the extracellular domain or alternative splicing in limited cases can generate a truncated, signaling remnant p95HER2 domain, which presents one potential mechanism of resistance to anti-HER2 therapies (8). Although trastuzumab forms the mainstay of anti-HER2 targeted therapies, it does not reverse HER2 protein expression in patients (9, 10). Inhibitors of the molecular chaperone HSP90, which elicit HER2 proteasomal degradation, are therefore currently under investigation in this context. A phase II clinical trial of one such inhibitor, NVP-AUY922 (Novartis), has recently been completed.
in patients with HER2 or ER positive locally advanced or metastatic breast cancer (NCT00526045).

Accurate testing of HER2 status is crucial for patient stratification to identify individuals that may benefit most from such targeted therapies, notably trastuzumab or pertuzumab. However, this can be intricate as HER2 expression may vary through progression from primary to secondary disease with locoregional and distant recurrences often not being amenable to biopsy (11). Furthermore, recent studies have highlighted spatial heterogeneity as a potential source of incorrect assessment (12). The vast majority of FDA-approved diagnostics are based on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). IHC determines the HER2 protein expression in formalin-fixed paraffin embedded (FFPE) tumor biopsies, while FISH detects HER2 gene amplifications, which are considered a legitimate surrogate as HER2 overexpression is generally caused by copy number variations (13). The utility of serum-based alternatives by detecting soluble extracellular domains is also under investigation (14).

Tumor marker-targeted molecular imaging using radiolabeled Affibodies, which are non-immunoglobulin-derived affinity proteins, might provide an accurate and non-invasive alternative to HER2 molecular diagnostics. Affibodies are engineered as three-helix bundle Z proteins derived from the staphylococcal protein A (15). They are characterized by nano- to picomolar binding affinities, small size of ~6.5 kDa compared to antibodies or antibody fragments (~20-150 kDa), and short plasma residence time, thus permitting rapid and homogenous tissue distribution. Consequently, high contrast images can be obtained within the first h or two of administration (16, 17). Due to their favorable pharmacokinetic properties,
these molecules are suitable for radiolabeling with short-lived radioisotopes by comparison with full IgG antibodies.

In the present study, we demonstrate that the HER2-targeting Affibody $^{18}$FGE-226 provides a viable strategy to determine differential HER2 expression irrespective of lineage or pretreatment with trastuzumab within 1 h after injection. We provide insights into the kinetic characteristics of the Affibody interaction with HER2 using full length versus p95HER2 transfected cells and siRNA HER2 as controls, or HSP90 inhibitor treatment to degrade HER2.
Materials and Methods

Chemistry and Radiochemistry

\[^{18}\text{F}\]GE-226 was labeled using a fluorobenzaldehyde (FBA) strategy optimized for automated manufacture on FASTlab, as outlined in Supplementary Fig. 1 and described elsewhere (18). Typical non-decay corrected end of synthesis yields were 30% and a radiochemical purity of 95%. The specific activity across all preparations was 38-110 GBq/\(\mu\)mol with a median of 46.2 GBq/\(\mu\)mol.

Cells and treatments

MCF7-vector (piRES), MCF7-p95HER2 and MCF7-HER2 cells were a kind gift of José Baselga’s laboratory (19). MCF7 clones, MDA-MB-231 (ATCC, Manassas, VA), MDA-MB-361 (Sigma-Aldrich), SKBR-3 (ATCC) and SKOV-3 (Sigma-Aldrich) cells were maintained in DMEM. AGS (Sigma-Aldrich), HGC-27 (Sigma-Aldrich), NCI-N87 (ATCC) and OE-33 (ATCC) cells were maintained in RPMI (Sigma-Aldrich). A431 cells (Sigma-Aldrich) were maintained in MEM Eagle medium (Sigma-Aldrich). Growth media were supplemented with 10% FCS (Lonza, Basel, Switzerland), glutamine and antibiotics (both Invitrogen, Paisley, United Kingdom). A431 cells were additionally supplemented with 1% non-essential amino acids. Cells were cultured at 37°C in humidified atmosphere containing 5% CO₂. Cell lines were authenticated by provider by short-tandem repeat analysis. No additional authentication of cells was done by the authors.

For siRNA-mediated HER2 knockdown, SKOV-3 cells were transfected with 25 nM scramble control (Dharmacon, Lafayette, CO, ON-TARGETplus Non-targeting Pool, Cat. Nr: D-001810-10-05) or HER2-targeting siRNA (Invitrogen ERBB2 Silencer® Select Validated siRNA; Cat. Nr:
4457298) by reverse transfection with Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s instructions. 3x10^5 cells were seeded in 12-well plates 48 h prior to uptake experiment. Target knockdown was verified by western blotting on cells that were transfected in parallel.

For all uptake studies in response to drug treatment, 2.5x10^5 SKOV-3 cells were seeded in complete medium 48 h prior to uptake experiments. Cells were incubated with indicated doses of NVP-AUY922 (LC Laboratories, Woburn, MA) for 24 h and 10 µg/mL trastuzumab (Roche, Basel, Switzerland) for 1 or 24 h prior to addition of radiotracer.

**In vitro uptake assay**

For baseline uptake, 3x10^5 cells were seeded in complete media in 12-well plates (Corning, Tewksbury MA) and allowed to recover overnight. Cells were washed twice with serum-free medium and pulsed with 370 kBq in 500 µL serum-free medium for one h. For blocking studies, cells were co-incubated with tracer and 0.5 mg/mL cold, isotopically unmodified GE-226. Cells were washed with PBS, trypsinized, neutralized with complete medium and centrifuged. The pellet was washed three times with PBS and lysed in 120 µL RIPA buffer (Sigma-Aldrich). The radioactivity of 100 µL lysate was counted on a Packard Cobra II gamma counter (Perkin Elmer). Radioactivity was normalized to applied radioactivity and protein content, as determined by BCA assay (Pierce).

**Small animal experimental models for PET**
All animal experiments were conducted by licensed investigators in accordance with the United Kingdom Home Office Guidance on the Operation of The Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 and within the published guidelines for the welfare and use of animals in cancer research (20). The \textit{in vivo} experimental models were established in female BALB/c nude mice aged 6-8 weeks (Harlan, Indianapolis, IN). For all but SKOV-3 xenografts, mice were subcutaneously (s.c.) implanted with 0.72 mg/60 day release estradiol pellets (Innovative Research of America, Sarasota, FL) approximately 2 days before cell inoculation. Xenografts were established by s.c. injection of 100 µL MCF7-vector, MCF7-p95HER2 and MCF7-HER2 cells (1.5x10^7 cells in PBS mixed 1:1 with Matrigel\textsuperscript{TM}, BD Biosciences, San Jose, CA), MDA-MB-361 cells (5x10^6 cells in PBS mixed 1:1 with Matrigel\textsuperscript{TM}) or SKOV-3 cells (5x10^6 cells in PBS) on the back of mice. Tumor dimensions were measured frequently by caliper measurements and volumes calculated by the following equation: $\text{volume mm}^3 = \frac{\pi}{6} \times a \times b \times c$, where $a$, $b$, and $c$ represent 3 orthogonal axes of the tumor. When tumor volumes reached approximately 50-100 mm\textsuperscript{3} (MCF7 models ~4 weeks post injection, MDA-MB-361 xenografts ~3 weeks post injection and SKOV-3 xenografts ~6 weeks post injection), mice were used for biodistribution or PET imaging studies.

For blocking studies, SKOV-3 xenograft bearing mice were administered 500 µg (~25 mg/kg) cold isotopically unmodified GE-226 intravenously (i.v.) through the tail vain 20 minutes before administration of radiotracer. To assess interaction of radiotracer with trastuzumab, SKOV-3 xenograft-bearing mice were treated with 50 mg/kg trastuzumab intraperitoneally (i.p.) 2 h prior to the scan. Animals were recovered, treated twice more with 25 mg/kg trastuzumab i.p. and re-scanned 7 days after initial dose. To investigate response to HSP90 inhibition, SKOV-3
xenograft-bearing mice were treated with 50 mg/kg NVP-AUY922 or equivalent volume of vehicle (~5 μL/g body weight; 10% DMSO and 5% Tween-20 in PBS) q.d. i.p. for three days. 24 h after the last treatment, animals were used for PET imaging.

**PET-CT imaging**

Mice were anesthetized through isoflurane inhalation and scanned on a small animal PET-CT scanner (Siemens Multimodality Inveon, Erlangen, Germany). Low dose CT scans were first acquired (80 kVp, 0.5 mA, 220 degree rotation, 600 ms per degree exposure time, 80 μm reconstruction pixel size) for PET attenuation correction and anatomical reference. PET images were acquired following a bolus i.v. injection of approximately 3.7 MBq [18F]GE-226 in the tail vein. Dynamic emission scans were acquired in list mode format over 60 minutes. Data were sorted into 0.5-mm sinogram bins and 19 time frames for image reconstruction by filtered back projection (4x15 seconds, 4x60 seconds and 11x300 seconds). The Siemens Inveon Research Workplace software was used for visualization of radiotracer uptake. 30 to 60-minute cumulative images of the dynamic data were employed to define 3-dimensional regions of interest (ROI). Arterial input function was estimated by drawing ROIs over the center of the heart cavity using cumulative images from 0.25 to 2 minutes of the dynamic series, a method, we previously validated for use in rodents (21). The count densities were averaged for all ROIs at each time point to obtain time versus radioactivity curves (TAC). Tumor TACs were normalized to injected dose measured by a VDC-304 dose calibrator (Veenstra Instruments, Joure, Netherlands) and normalized uptake was expressed as percentage injected dose per mL tissue (NUV; %ID/mL). Normalized uptake of radiotracer at 60 minutes (NUV_{60}) was used for
comparisons. For qualitative image visualization, cumulative images of the dynamic data (30 to 60 min) were also iteratively reconstructed (OSEM3D).

**Kinetic modeling**

Kinetic analysis of PET data was performed applying a standard two-tissue irreversible compartmental model to fit each tumor TAC with the corresponding image-derived plasma TAC as input function (IF) to estimate $K_1$ (mL/cm$^3$/min), $k_2$, (1/min) and $k_3$ (1/min) and the blood vascular component $V_b$ (mL blood/mL tissue; unitless). The irreversible uptake rate $K_i$ (mL/cm$^3$/min) was computed as $K_1 \times k_3 / (k_2 + k_3)$. To estimate the kinetic parameters the measured tumor TAC (tTAC) was modeled as

$$tTAC(t) = (1 - V_b)h(t) \otimes IF(t) + V_bIF(t)$$

with $h(t)$ indicating the unknown tissue impulse function and $\otimes$ the convolution operator. The parameter vector $p = [K_1, k_2, k_3, V_b]$ was estimated with the standard Weighted Non-Linear Least Squares (WNLLS) by minimizing the Weighted Residual Sum of Squares (WRSS) function

$$WRSS(p) = \sum_{i=1}^{N} w_i [tTAC(t_i, p)^\text{MODEL} - tTAC(t_i)]^2$$

with $tTAC(t_i)$ and $t_i$ indicating the measured concentration in the tumor and mid-time of i-th frame, respectively, and $N$ denoting numbers of frames. Weights were set to

$$\frac{\Delta_i}{C(t_i) \exp(\lambda t_i)}$$

with $\Delta_i$ and $\lambda$ representing the duration of the i-th frame and decay-constant of $^{18}$F (22). The two-tissue irreversible model was chosen after visual assessment of the tumor TACs, which showed clear irreversible uptake in most cases. Furthermore, when a two-tissue reversible
compartment model was used, non-physiological estimates of the parameters characterized by high variance were obtained.

**Statistical analysis**

Data were expressed as mean ± standard deviation (SD) or standard error of the mean (SEM). Unless otherwise specified, the significance of comparison between two data sets was determined using unpaired, two-tailed Student’s t test (GraphPad Prism version 5.1) and $P < 0.05$ defined as significant.

The Supplementary Information contains further experimental procedures including: synthesis of fluorescein labeled GE-226, surface plasmon resonance, western blotting, biodistribution, metabolic stability, small animal models for fluorescent GE-226 experiments, immunohistochemistry, ELISA and sequencing.
Results

Affibody-HER2 binding properties

To ensure the fluorinated prosthetic group does not adversely influence the Affibody binding kinetics, we measured the receptor interaction of the isotopically unmodified Affibody analogue using surface plasmon resonance and compared this to binding of human full-length and truncated p95HER2, as well as rhesus and rat full-length HER2. While the tracer showed very strong binding to human ($K_D = 76$ pM) and rhesus HER2 ($K_D = 67$ pM), it did not interact with p95HER2 or rat HER2 (Table 1, Supplementary Fig. S2).

$^{[18F]}$GE-226 exhibits specific and lineage-independent HER2 binding

We tested the tracer retention in 10 different cell lines derived from breast, upper gastrointestinal tract and ovarian cancer, of which half were HER2 negative and the other half HER2 positive. The panel included an isogenic model comprising of HER2 negative MCF7 cells, which were transfected with empty vector (MCF7-vector), p95HER2 (MCF7-p95HER2) or full-length HER2 (MCF7-HER2). While all HER2 negative and p95HER2 transfected cell lines had only marginal background uptake (1.2 ± 0.5% applied radioactivity per mg protein across all lines), all HER2 positive cell lines retained the tracer at high levels (between 13.6 ± 3.4 and 79.9 ± 12.1% applied radioactivity per mg protein) and in good agreement with endogenous HER2 expression. Tracer binding was, however, independent of expression of another epidermal growth factor receptor family member, EGFR. Fig. 1A shows one representative uptake experiment, as initial experiments revealed that the uptake was dependent on the specific activity. In comparison to freshly prepared $^{[18F]}$GE-226, the same radiotracer preparation
yielded only 39.5 ± 8.5 and 24.9 ± 3.8% tracer uptake if incubation was initiated 70 and 140 minutes later (Supplementary Fig. S3).

To further investigate the specificity of the signal, we co-incubated SKOV-3 cells with tracer and large excess (~2000 fold) of its non-radioactive \(^{19}\)F-labeled analogue (Fig. 1B). This reduced uptake to 3.1 ± 2.6% compared to control cells (100 ± 12%; \(P < 0.0001\)). Furthermore, transient siRNA-mediated knockdown of HER2 decreased tracer uptake compared to non-targeting scramble control (Fig. 1C, 100 ± 12% versus 18 ± 9%, \(P < 0.0001\)). Target knockdown was confirmed by western blot.

[^18F]GE-226 exhibits a different binding site than trastuzumab and predicts detection of HER2 degradation by NVP-AUY922

An important question when developing a HER2-targeting imaging probe is whether the tracer can correctly determine the HER2 status of a patient independently of potential trastuzumab treatment. Pre-treatment of SKOV-3 cells with 10 μg/mL trastuzumab for 1 h did not alter tracer binding, however, incubation for 24 h prior to uptake experiment reduced tracer binding by 32 ± 11% compared to drug-naïve controls (Fig. 2A; \(P < 0.0001\)).

We hypothesized that HER2 degradation consequent to HSP90 inhibition (HER2 is a client protein of HSP90 (23)) would result in detectable changes in tracer uptake. The HSP90 inhibitor NVP-AUY922 caused a dose-dependent decrease of HER2 protein expression compared to untreated controls, which consequently translated into reduced tracer uptake, further supporting its specificity (Fig. 2B; \(P < 0.0001\) for all tested concentrations compared to control).

[^18F]GE-226 discriminates differential HER2 expression in vivo
Based on the *in vitro* data, we wanted to scrutinize the ability of the tracer to distinguish varying degrees of HER2 expression in the complex tumor milieu *in vivo*. Fig. 3A shows representative small-animal [\(^{18}\text{F}\)]GE-226 PET images of SKOV-3 and MCF7-vector xenograft-bearing mice. High tumor uptake contrasts the low non-specific retention in the body. The tracer was metabolically stable and predominately and rapidly excreted via the renal route (Supplementary Fig. S4 and Supplementary Table S1). Across different tumor models, the tracer discriminated well between HER2 positive and negative xenografts. Both tumor-specific distribution and retention kinetics accounted for these differences. While HER2 negative MCF7-vector and MCF7-p95HER2 xenografts exhibited low tumor retention and a steady-state tissue radioactivity after initial delivery, HER2 positive xenografts had increased uptake and followed a pattern of net irreversible binding (Fig. 3B). Thus [\(^{18}\text{F}\)]GE-226 PET was able to distinguish HER2-negative (MCF7-vector and MCF7-p95HER2) from low (MCF7-HER2) and moderately (MDA-MB-361) HER2-expressing xenografts. However, tissue radioactivity was comparable in tumors with moderate and highly (SKOV-3) HER2-expression when simple measures of uptake were employed for PET analysis. Nonetheless, radiotracer uptake correlated well with HER2 protein expression as determined by ELISA \((r^2 = 0.78; \text{Fig. 3C and Supplementary Fig. S5})\).

We hypothesized that kinetic modeling, which accounts for tissue uptake relative to plasma as opposed to tissue uptake alone, could further help discern the various HER2 groups. We employed a two-tissue irreversible compartmental model to derive the net irreversible uptake rate constant, \(K_i\) (Fig. 3D). No metabolite correction was necessary as the tracer was stable *in vivo* (Supplementary Fig. S4A). With this model, we could distinguish all groups, even MDA-MB-
361 from SKOV-3 xenografts (Fig. 3D). As expected, $K_i$ highly correlated with NUV$_{60}$ among all groups ($r^2 = 0.82; P = 0.008$; Fig. 3E).

To lend further support to the specificity of the Affibody, we carried out blocking studies by injecting 30 mg/kg isotopically unmodified GE-226 i.v. 20 minutes prior to PET scan (~100-fold mass equivalent of hot tracer). The cold ligand, by blocking specific binding sites, resulted in significantly reduced tracer uptake (NUV$_{60}$ 18.7 ± 2.4 versus 7.1 ± 1.6 in controls and blocked tumors, $P = 0.0003$) and $K_i$ (Supplementary Fig. S5). It is noteworthy that the kinetics of tracer uptake were distinctly different between controls and blocked samples, in that the latter share characteristics of HER2 negative tumors.

**Localization and intensity of fluorescein-labeled GE-226 correlates with DAKO HercepTest™**

To examine tissue localization, we labeled GE-226 with fluorescein and compared localization and fluorescent intensity in tumor sections with FDA approved DAKO HercepTest™. In contrast to PET experiments, normalization to injected dose is not possible with fluorescent compounds. To eliminate inter-subject variability, we performed experiments in bilateral tumor-bearing mice. Because HER2 positive and negative xenografts described in Fig. 3 have greatly varying growth rates and require differential hormonal treatments, we employed A431 (HER2 negative) and NCI-N87 (HER2 positive) xenografts as previously described (18). A mixture of 20 mg/kg Hoechst and 15 mg/kg fluorescein-conjugated GE-226 in PBS were injected i.v. and two h post injection, tumors were excised, formalin fixed and paraffin embedded and adjacent tumor sections prepared for HercepTest™ staining or fluorescent microscopy. Tissue processing for immunofluorescence microscopy removed any unbound tracer and signal therefore accounts
only for specific HER2-Affibody interaction. Fig. 4 shows that fluorescent staining co-localized with regions that are HER2 positive in NCI-N87 tumors and that both HercepTest™ and fluorescent staining in A431 tumors were negligible.

**[^18F]GE-226 can correctly assess HER2 status independently of prior trastuzumab treatment and predicts for response to NVP-AUY922 in vivo**

SKOV-3 tumor bearing mice were treated with three doses of trastuzumab and imaged 2 h post initial dose and re-imaged 48 h after last treatment (i.e. 7 days after initial scan). Neither treatment did not adversely affect tumor tracer retention (Fig. 5A), albeit 7 days of continuous treatment reduced $K_i$ by 24% ($P = 0.025$) as a consequence of elevated arterial input function and altered renal excretion (Fig. 5B, Supplementary Fig. S6). This confirmed by comparison to trastuzumab, that the Affibody possesses different HER2 binding sites. Interestingly, one mouse had significantly reduced uptake on both scans and was viewed separately for analysis. We could not correlate tracer uptake with ELISA-derived HER2 expression values, as one of the ELISA antibodies interfered with bound trastuzumab. We therefore confirmed by western blot that trastuzumab treatment did not substantially alter HER2 expression nor resulted in expression of truncated P95HER2 in the outlier sample (Supplementary Fig. S7A). Sequencing exon 8 of HER2, which has been previously described as a site for mutations on the extracellular domain of HER2 (24), indicated no sequence alterations in the outlier sample compared to controls (Supplementary Figure S7B). Furthermore, kinetic modeling revealed increased tissue efflux ($k_2$) of the outlier with similarities to HER2 negative tumors, suggesting a loss of interaction of the Affibody with its target (Supplementary Fig. 7C-G). Finally, we wanted to
assess whether $^{18}$FGE-226 is responsive to HSP90 inhibitor treatment in vivo. We treated SKOV-3 xenograft bearing mice with 3 doses of 50 mg/kg NVP-AUY922 or vehicle. This led to reduced HER2 expression with consequently decreased tracer uptake (Fig. 5C-D, Supplementary Fig. S8B).
Discussion

With aid of kinetic modeling, we demonstrate that the $\text{Z}_{\text{HER2:2891}}$ Affibody, $[^{18}\text{F}]\text{GE-226}$, quantitatively discriminates between HER2 negative and positive tumors within 1 h, independent of lineage and prior treatment with trastuzumab. Affibody radiotracers have been developed to overcome the shortcomings of large (150 kDa) antibodies. To date most of the reported studies of radiolabeled Affibodies in the literature have employed analogs of $\text{Z}_{\text{HER2:342}}$ labeled with radiometals or radiohalogens (17, 25-31). Recently, re-engineering of this Affibody by Feldwisch and co-workers (32) led to an optimized scaffold containing 11 amino acid substitutions in the nonbinding surface of the Affibody removing similarity to the original protein A domain - $\text{Z}_{\text{HER2:2891}}$. Further to potential for automated site-specific good manufacturing practice-grade (GMP (33)) manufacture on FASTlab to allow broad clinical access to a HER2 imaging agent, $\text{Z}_{\text{HER2:2891}}$ has improved thermal and chemical stability by avoiding deamidation, as well as increased hydrophilicity of the non-binding surface; positive attributes for ease of peptide synthesis and in vivo pharmacokinetics. The latter property is desirable to permit conduct of imaging studies within 1-2 h post-radiotracer injection. However, within this early period non-specific uptake could contribute to tissue signal. We therefore assessed the specificity of $^{18}\text{F}$-radiolabeled $\text{Z}_{\text{HER2:2891}}$ Affibody, $[^{18}\text{F}]\text{GE-226}$, for early imaging (1 h) using both intrinsic cellular uptake and in vivo dynamic imaging to quantitatively discriminate between HER2 negative and positive tumors.

Optimization of contrast is pivotal to successful development of imaging agents. High contrast results largely from high affinity of radiotracers and rapid pharmacokinetics. By comparison with other molecular imaging probes, Affibodies benefit from a short blood circulation time and
high target affinity resulting in high contrast images within a relatively short time after injection, and slower internalization rates (26, 34, 35). This permits utilization of more widely available short-lived radioisotopes, such as $^{18}$F and $^{68}$Ga, minimizing the patient’s dosimetry. In comparison with nanobodies, Affibodies excel through lower $K_D$, higher $k_{on}$ and slower $k_{off}$ rates (36). Regarding affinity, Surface Plasmon Resonance experiments with isotopically unmodified GE-226 revealed high affinity binding to human and rhesus HER2-ECD-Fc comparable to the binding of parent $Z_{HER2:2891}$ Affibody to human HER2-ECD-Fc (76pM (32)). In contrast, GE-226 did not interact with rat HER2-ECD-Fc or human p95HER2, demonstrating specificity to the ECD-containing human protein. Radiofluoridation to produce $[^{18}\text{F}]$GE-226 did not affect radiotracer affinity either, as demonstrated by high specific cell intrinsic uptake in HER2 positive versus negative human breast, upper-gastrointestinal and ovarian cancer cell lines. Notably the lineage independence observed also lends support to the specificity of the radiotracer for HER2 versus other targets like EGFR and potential utility in cancers other than breast.

While preclinical imaging with $Z_{HER2:2891}$ radiolabeled with $^{111}$In for single photon computed emission tomography (SPECT) displays good tumor targeting in SKOV-3 xenografts (34), it is expected that $[^{18}\text{F}]$GE-226 with the superior sensitivity, resolution, and quantification of PET will provide improved contrast at the early time points.

Regarding systemic tracer disposition, high renal accumulation is characteristic of radiometal tracers due to loss of the radioactive ion and reabsorption in the proximal tubules (37). In this context previous Affibodies labeled with $^{68}$Ga or $^{111}$In showed approximately 10-fold higher renal localization than that seen in tumor (34, 35, 38), precluding imaging of tumors in the region around the kidney, as well as having an impact on dosimetry. Bioconjugation of the
Affibody molecule with albumin, histidine containing tags or $^{18}F$ radiolabels have been proposed as alternative approaches to avoid tubular reabsorption and permitting rapid glomerular filtration (26, 39-41). Using a radiohalogen strategy with $^{18}F$, we demonstrated rapid renal clearance of $[^{18}F]GE-226$, without substantial tracer accumulation in the kidneys; kidney radioactivity levels were comparable to levels in tumors at 60 min. Uptake in other organs, including the liver, was negligible and it remains elusive whether previously detected hepatic uptake of other Affibodies in the clinical setting is attributed to Affibody disposition or the labeling strategy (42).

This suggests that $[^{18}F]GE-226$ could be used for detection of HER2 expression in primary tumors and distant metastasis, including liver, lung and bone. In our study, $[^{18}F]GE-226$ did not cross the blood-brain-barrier so its utility for imaging of brain metastases remain to be seen.

Several lines of evidence indicated that the binding of $[^{18}F]GE-226$ to HER2 is highly specific: a) the tracer discriminated between HER2 positive and negative cells and tumors, b) siRNA knockdown of HER2 protein in cells reduced tracer uptake, c) pre-treatment of cells or mice with isotopically unmodified GE-226 resulted in significant reduction in uptake and d) tumor distribution of fluorescein-labeled GE-226 co-localized with HER2 protein as determined by DAKO HercepTest™. The latter also demonstrated that tumor distribution of the Affibody was non-limiting in the heterogeneous tumor models studied. We intimate that the above desirable affinity, specificity and pharmacokinetics properties of $[^{18}F]GE-226$ led to very high contrast PET images. We acknowledge that the high contrast images are perhaps due also in part to the lack of tracer binding to rodent HER2 (Supplementary Fig. S2), nonetheless, it further substantiates
the low non-specific binding of [\(^{18}\)F]GE-226 as rodent data for Affibodies have been shown to translate well into human imaging profile.

We observed an influence of specific radioactivity on Affibody uptake \textit{in vitro} where receptor numbers are limited in part due the 2D properties of \textit{in vitro} culture, compared to a 3D system \textit{in vivo}. We hypothesize that with the higher amount of cold compound associated with the same level of radioactivity over time, the limited specific binding sites of an \textit{in vitro} culture system are more readily blocked and result in a time-dependent decrease of tracer uptake. As this effect was not observed \textit{in vivo} – potentially due to a much greater overall availability of receptors – we do not anticipate this finding to hamper clinical development.

PET imaging demonstrated rapid tracer uptake in HER2 positive xenografts with net irreversible binding kinetics over time. The irreversible uptake (over the time of imaging) made it possible to distinguish between HER2 negative and HER2 positive tumors within 1 h. Time versus radioactivity curves revealed steady-state (limited-washout) background uptake in HER2 negative xenografts, which was in keeping with the normal distribution kinetics of these types of peptides within the literature (26, 38, 43). In HER2 negative xenografts (e.g., MCF7 and MCF7 p95HER2), uptake was rapid and remained stable over the 60-minute scan period. As wash-out mechanisms are primarily determined by size, tissue retention of Affibodies is longer than of small-molecules nonetheless more favorable than full immunoglobulins. Thus, the uptake observed in HER2 negative tumors can be attributed to non-specific background tissue distribution. In contrast, all HER2 positive models showed a continuous increased uptake throughout image acquisition timeframe. We confirmed that the net irreversible trapping of the tracer in tumor was not due to differences in tracer delivery ($K_1$) or blood volume ($V_b$) but...
rather to specific uptake. Tumor uptake correlated with HER2 expression and we attribute this to specific Affibody-HER2 interaction, and possibly some receptor internalization (26, 34, 35). Receptor internalization was not assessed in this study but localization of the fluorescein-labeled labeled Affibody in vivo did not suggest substantial internalization within the timeframe of the study. Importantly, kinetic modeling permits definition of a threshold for HER2 positivity by determining the irreversible uptake in HER2 positive tumors. This concept requires clinical evaluation, but preliminary data indicate reliable detection of HER2 positive and negative lesions. Notably, a negative scan will be a clinically determined quantitative or semi-quantitative uptake cut-off value at a defined post-injection time, e.g. 1h, due to Affibody tracer distribution kinetics, and not, an absolute negative signal as seen by immunohistochemistry.

In view of trastuzumab being the most important HER2-targeting therapy, we wanted to ensure that tracer and antibody did not compete for the same extracellular epitope. X-ray crystallography revealed that $Z_{HER2}$ Affibodies bind the extracellular domain of HER2 at the interface of domains III and IV, distinct from the trastuzumab binding site on domain IV (44). We confirmed, both in vitro and in vivo, that uptake of $[^{18}\text{F}]\text{GE-226}$ was not obscured by the presence of trastuzumab. Minor, but significant, decreases in uptake after 24 h pre-treatment with trastuzumab in vitro are more likely related to altered receptor internalization or other dynamics due to the high concentration used (45, 46). Continuous exposure of SKOV-3 xenografts to trastuzumab resulted in a slight downregulation of HER2 protein expression, as detected by western blot. This contrast to clinical data has been previously reported for pre-clinical models (27), but further validation would be required to investigate which of the
complex dynamic changes upon trastuzumab treatment – including receptor internalization, changes in vascularization, immune response, cell death and selection of HER2 negative sub-populations – account for these discrepancies. In the in vivo studies, one HER2 tumor bearing mouse was characterized by low tumor tracer uptake. As HER2 was found not to be truncated in this sample (western blot analysis), mutations in the extracellular domain of HER2 were examined. Recent reports indicate that amino acids 309 and 310 on exon 8 are prone to mutations (G309A/E, S310F (24, 47)), a site that has previously not been identified to contribute to the HER2-Affibody interaction (44). As expected, no point mutations occurred in the outlier samples. Higher tissue efflux kinetics ($k_2$) paired with a lowered $K_1$ are indicative of lack of retention or potential perfusion deficits, causing reduced tracer delivery. If perfusion deficits are responsible for this unexpected finding, then an adverse implication on correct assessment of HER2 positivity by this technology is envisaged; the comparable clinical scenario is, however, unlikely to affect treatment stratification, as poor perfusion would potentially also reduce efficacy of trastuzumab.

Finally we confirmed that [$^{18}$F]GE-226 is suitable as pharmacodynamic marker of HSP90 inhibition and perhaps as patient enrichment tool for those likely to benefit from such therapies. The most promising of these drugs, NVP-AUY922 (48) is currently in Phase II clinical trials and has previously shown to downregulate HER2 expression (49), which was correctly confirmed in vitro and in vivo by [$^{18}$F]GE-226 PET. This is in accordance with the report by Smith-Jones and co-workers who similarly demonstrated that the HSP90 inhibitor, 17-allylamino geldanamycin, degrades HER2 leading to reduction in the uptake of [$^{68}$Ga]-labeled F(abi)$_2$ fragment of trastuzumab (43, 50).
In conclusion, $^{[18F]}$GE-226 PET imaging permits accurate discrimination of HER2 receptor expression, irrespective of tumor heterogeneity, cell lineage, or prior trastuzumab treatment. We expect the tracer to have good safety and dosimetry profiles due to its low nonspecific binding, the use of short-lived radiolabel and its favorable pharmacokinetic properties. These data support the clinical development of this tracer in cancer patients, which is planned.
Acknowledgments

We thank Matthias Glaser and Bob Forrest for supporting radiochemistry and Michael Jones with sequencing support.

Author Contributions

Conception and design: Eric O. Aboagye, Duncan Hiscock, Sebastian Trousil, Susan Hoppmann

Development of methodology: Eric O. Aboagye, Duncan Hiscock, Sebastian Trousil, Susan Hoppmann, Peter Iveson

Acquisition of data: Sebastian Trousil, Susan Hoppmann, Quang-Dé Nguyen, Maciej Kaliszczak, Peter Iveson

Analysis and interpretation of data: Sebastian Trousil, Susan Hoppmann, Giampaolo Tomasi, Duncan Hiscock, Eric O. Aboagye

Writing, review and/or revision of the manuscript: Sebastian Trousil, Eric O. Aboagye, Susan Hoppmann, Duncan Hiscock Giampaolo Tomasi

Study supervision: Duncan Hiscock, Eric O. Aboagye
References


## Table

### Table 1

<table>
<thead>
<tr>
<th>Kinetic properties</th>
<th>Human HER2</th>
<th>Rhesus HER2</th>
</tr>
</thead>
<tbody>
<tr>
<td>On-rate $k_{on}$</td>
<td>$1.73 \times 10^7 \text{ M}^{-1} \text{s}^{-1}$</td>
<td>$6.37 \times 10^6 \text{ M}^{-1} \text{s}^{-1}$</td>
</tr>
<tr>
<td>Off-rate $k_{off}$</td>
<td>$1.31 \times 10^3 \text{ s}^{-1}$</td>
<td>$4.25 \times 10^4 \text{ s}^{-1}$</td>
</tr>
<tr>
<td>Affinity $K_D$</td>
<td>$7.58 \times 10^{-11} \text{ M}$</td>
<td>$6.67 \times 10^{-11} \text{ M}$</td>
</tr>
<tr>
<td>$R_{max}$</td>
<td>133.5</td>
<td>138.1</td>
</tr>
<tr>
<td>Chi-Square $X^2$</td>
<td>0.607</td>
<td>1.12</td>
</tr>
<tr>
<td>U-value</td>
<td>3</td>
<td>7</td>
</tr>
</tbody>
</table>
Tables and Figure legends

Table 1: Summary of binding kinetics of GE-226 to human and rhesus HER2.

Figure 1. \[^{18}F\]GE-226 binds with high selectively and sensitivity to HER2. (A) Cell lines of diverse lineages and differential HER2 status were exposed to \[^{18}F\]GE-226 for 60 minutes and retained radioactivity measured as percent applied radioactivity normalized to total protein (mean of n=1 with 5-6 replicates ± SD). Full-length and truncated p95 HER2 protein expression as determined by western blot is shown for the same cell lines in the panel above. (B) SKOV-3 cells were incubated with \[^{18}F\]GE-226 in the presence or absence of 0.5 mg/mL blocking dose of isotopically unmodified GE-226 for 60 minutes and cell-bound activity measured (\(P < 0.0001\); mean of n=3 in triplicate on three different days ± SD). (C) HER2 expression was transiently abrogated by siRNA and tracer retention after 60 minutes compared to non-targeting scramble control (\(P < 0.0001\); mean of n=3 in triplicate on three different days ± SD); knock-down confirmed by western blot.

Figure 2. \[^{18}F\]GE-226 possesses a different binding site than trastuzumab and detects HER2 degradation upon HSP90 inhibition. (A) SKOV-3 cells were treated with 10 \(\mu\)g/mL trastuzumab for 1 or 24 h and incubated for an additional h with \[^{18}F\]GE-226 and retained activity compared to untreated controls (*** \(P < 0.0001\); mean of n=5 in triplicate on five different days ± SD). Effect on HER2 protein expression is shown in the panel below. (B) Effect of HSP90 inhibitor
NVP-AUY922 on HER2 expression and consequent impact on tracer uptake ($P < 0.0001$ for all concentrations compared to control; mean of $n=3$ in triplicate on three different days ± SD).

**Figure 3.** Tumor profiles of $[^{18}F]GE-226$ in differentially HER2 expressing xenograft models. (A) Representative OSEM3D reconstructed PET-CT images of SKOV-3 and MCF7-vector xenograft-bearing mice. White arrow indicates tumor, orange arrow kidney. (B) Comparison of tumor time versus radioactivity curves in indicated xenograft models (mean of $n=6$ ± SEM with exception of MCF7-p95HER2 $n=3$ ± SEM). (C) Correlation between NUV$_{60}$ and HER2 expression as determined by ELISA on tumor samples, that were excised post imaging. (D) Tissue pharmacokinetic analysis using a single input 2-tissue 3k model to derive $K_i$, the rate constant for the net irreversible retention of the tracer in the tumor.

**Figure 4.** GE-226 co-localizes with HER2 protein expression in tumors with spatial heterogeneity. GE-226 was labeled with fluorescein and injected in mice bearing both NCI-N87 and A431 tumors, which express high and low levels of HER2, respectively. Tumors were sectioned and adjacent slides either stained with DAKO HercepTest™ or used for immunofluorescent microscopy.

**Figure 5.** $[^{18}F]GE-226$ binding does not interfere with trastuzumab treatment and can predict response to HSP90 inhibition. (A) Mice bearing SKOV-3 xenografts were treated with 50 mg/kg trastuzumab i.p. 2 h prior to scan. Animals were recovered, treated twice more with 25 mg/kg trastuzumab and re-imaged 7 days after initial scan ($n=6$ ± SEM). One mouse, which was an
outlier with low tracer uptake both on early and late scan, is displayed separately. (B) Pharmacokinetic analysis of A ($P = 0.025$). (C) Comparison of NVP-AUY922 treatment ($n=5 \pm \text{SEM}$) to vehicle treated controls ($n=4 \pm \text{SEM}$) in the SKOV-3 xenograft model and (D) kinetic analysis of inhibition constants ($P = 0.011$).
Clinical Cancer Research

Positron Emission Tomography Imaging with $^{18}$F-Labeled Z \textit{HER2:2891} Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

Sebastian Trousil, Susan Hoppmann, Quang-De Nguyen, et al.

Clin Cancer Res  Published OnlineFirst February 3, 2014.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-2421

Supplementary Material  Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2014/02/04/1078-0432.CCR-13-2421.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.